A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis
Latest Information Update: 19 Dec 2025
At a glance
- Drugs Netakimab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors SPH-BIOCAD
Most Recent Events
- 19 Dec 2025 New trial record